PERSONALISED HEALTHCARE &
CSF BIOMARKERS

Mastering a P4 Medicine approach to transform your CNS Drug Discovery in the 21st Century

In the Chair:

Dr. Samantha Budd Vice President Translational Sciences CNS & Pain IMed

ASTRAZENECA

In your eminent Speaker Panel:

Professor Agneta Nordberg
MD PhD Professor, Director, Alzheimer Neurobiology Center
KAROLINSKA INSTITUTE

Dr. Magnus Sjögren Vice President Global Exploratory Development
UCB S. A.

Dr. Hugh Salter Principal Scientist
ASTRAZENECA

Dr. Holly D. Soares Director Clinical Biomarkers Neuroscience
BRISTOL-MYERS SQUIBB COMPANY (USA)

Dr. Caroline Graff Associate Professor, Department of Neurobiology, Care Sciences and Society
KAROLINSKA INSTITUTE

Dr. Oskar Hansson Associate Professor Clinical Memory Research Unit, Department of Clinical Sciences Malmö
LUND UNIVERSITY

Elisabetta Vaudano DVM PhD Principal Scientific Officer
INNOVATIVE MEDICINES INITIATIVE JOINT UNDERTAKING (IMI)

Event Summary:

The Life Science industry moves in the direction towards predictive and preventive medicine, Personalised Healthcare. This is a paradigm shift from today's reactive medicine to proactive medicine in the future. By applying pharmacogenomics it is possible to give the right drug at the right time in order to customise drug therapies to individual patients genetic make up.

Neurodegenerative diseases are a heterogeneous condition with a need to deliver customised treatments to slow down or prevent further progression. By looking at CSF biomarkers it is possible to find out which patient groups that responds on different treatments. Today CSF Aβ1-42, total CSF tau protein and P-Tau18P represent three levels of biomarkers to enable physicians to identify early stage of the Alzheimer's disease and other neurodegenerative diseases' pathogenic progression. By combining genetic and molecular approaches to identify individual patient groups, scientists are able to develop a predictive, preventive, personalised and participatory healthcare programme to improve elderly people's well-being in the coming years.

This flagship event will examine the role of a P4 Medicine approach to fully capture the potential of CSF biomarkers to customise treatments to prevent or slow down the progression of neurodegenerative diseases. Our distinguished speaker panel will provide your CNS Drug Discovery organisation with a platform to successfully design personalised treatments to tackle neurodegenerative conditions such as Alzheimer's and Parkinson's disease, frontotemporal dementia and related Tauopathies.

This event will tackle key issues such as:

• Personalising healthcare to improve cognition for your patients with Amyotrophic Lateral Sclerosis (ALS)
• Amyloid-β Immunotherapy: Exploring CSF biomarkers & imaging technology to identify at-risk individuals for Alzheimer's disease
• Providing better healthcare through P4 Medicine by engaging your patients
• How do you combine genetic studies with molecular biology to identify risk profile for Alzheimer's disease?
• Mastering personalised healthcare & CSF biomarkers to enhance preclinical diagnosis of Parkinson's disease
• Addressing new treatments to target molecular processes and improve cognitive dysfunctions in the human brain
• Communicating the meaning of Personalised Healthcare to achieve support from your patients and physicians
• Exploring a biomarker-driven identification of prodromal AD patient population groups to maximise the success of your clinical trials
• Embracing systems biology to understand the connection between brain health and other chronic diseases in the human body
• The CSF biomarker's promise – Facilitating the selection voyage by only taking the most hopeful drug candidates on board
  

Target audience and Job titles:

Presidents, Chief Executive Officers, Chief Scientific Officers, Chief Medical Officers, Vice Presidents, Directors and Heads within:

• CNS Drug Discovery
• Bioinformatics
• CNS Clinical Biomarkers
• Translational Sciences
• In vivo Pharmacology
• Clinical Development
• Genomics
• Informatics
• Integrative Neurosciences & Biomarkers
• Neurodegenerative Diseases
• Statistical Biomarkers
• Early Clinical Development, Neurology
• Global Clinical Development
• Parkinson's Disease
• Molecular Biology
• ALS
• Preclinical Research and Development
• Dementia
• Translational Medicine, Neuroscience
• Clinical Neuroscience
• Clinical Biomarkers Neuroscience
• Research & Development
• Pharmacogenomics
• Clinical Pharmacology
• Alzheimer's Disease R & D
• Molecular and Developmental Genetics
• Discovery Research and Preclinical Development
• Clinical Development Neuroscience
• Molecular Neurobiology
• Pharmacogenetics
• Neuroscience Research
• Neurology and Neurological Sciences
• Neurobiology
• Medical Advisory
• Business Development